Core Insights - Cytek Biosciences reported a total revenue of $57.5 million for Q4 2024, a slight decrease of 1.3% from $58.2 million in Q4 2023, but a 1.4% increase on a non-GAAP constant currency basis [4][11] - The company achieved a gross profit of $33.7 million in Q4 2024, reflecting a 1.8% increase from $33.0 million in Q4 2023, with a gross margin improvement to 59% from 57% [5][12] - For the full year 2024, total revenue reached $200.5 million, marking a 3.9% increase over 2023, with adjusted EBITDA rising significantly by 77% to $22.4 million [11][17] Financial Performance - Q4 2024 operating expenses were $30.7 million, with a non-recurring benefit of $2.6 million from a license and royalty settlement adjustment; excluding this, non-GAAP operating expenses remained unchanged from Q4 2023 [6][8] - The net income for Q4 2024 was reported at $9.6 million, which included non-recurring benefits totaling $8.8 million; without these, non-GAAP net income would have been $2.9 million, down from $5.5 million in Q4 2023 [9][10] - For the full year 2024, the net loss was $6.0 million, an improvement from a net loss of $12.1 million in 2023, with total adjusted EBITDA for the year at $22.4 million compared to $12.6 million in 2023 [16][17] Operational Highlights - The installed base of Cytek instruments expanded to 3,034, with 667 new instruments placed during 2024 [7] - A new manufacturing facility was opened in Singapore to enhance capacity and global supply flexibility [17] - The company repurchased 3,971,624 shares at a cost of approximately $21.6 million and announced a new stock repurchase program for up to $50 million in 2025 [7][17] Future Outlook - Cytek expects total revenue for 2025 to be between $204 million and $212 million, indicating a growth of 2% to 6% over 2024 [19]

Company Overview - Cytek Biosciences, Inc. is a leading cell analysis solutions company that specializes in high-resolution, high-content, and high-sensitivity cell analysis using its patented Full Spectrum Profiling™ (FSP™) technology [2][3] - The company's product offerings include the Cytek Aurora™ and Northern Lights™ systems, the Cytek Aurora CS cell sorter, and the Cytek Orion™ reagent cocktail preparation system, among others [2][3] Financial Announcement - Cytek Biosciences will report its financial results for the fourth quarter and full year 2024 after market close on February 27, 2025 [1] - A conference call will be held at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results, business developments, and outlook [1] Communication Channels - The company utilizes its website, LinkedIn page, and X (formerly Twitter) account for distributing information about its products, financial announcements, and other material information [4]

Core Viewpoint - Cytek Biosciences, Inc. anticipates a revenue growth of approximately 4% for the full year 2024, with preliminary revenue estimates between $200 million and $201 million, despite facing foreign exchange challenges [2][3]. Financial Performance - The expected revenue for 2024 is projected to be between $200 million and $201 million, compared to $193 million in 2023, indicating a growth of 4% [2]. - The anticipated revenue for the fourth quarter of 2024 is between $57 million and $58 million, reflecting an 11% to 13% increase from the third quarter of 2024, but a decline of 2% to flat compared to the fourth quarter of 2023 [2]. - The appreciation of the US dollar negatively impacted fourth quarter revenue by approximately $1.5 million [2]. Market Insights - Cytek's revenue in the Asia Pacific and Rest of World markets showed strong growth, although overall fourth quarter results were slightly below expectations due to currency appreciation and order delays [3]. - The company remains optimistic about its long-term potential and business strategy, highlighting a significant opportunity for its advanced cell analysis tools [3]. Upcoming Events - Cytek will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, providing an opportunity for investors to gain insights into the company's performance and strategy [4]. Company Overview - Cytek Biosciences specializes in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ technology to deliver high-resolution and high-sensitivity analysis tools [5]. - The company's product offerings include the Cytek Aurora™ and Northern Lights™ systems, among others, aimed at providing a comprehensive suite of solutions for customers [5].

Core Insights - Cytek Biosciences, Inc. (NASDAQ: CTKB) was initially rated as a "Buy" before its public offering on July 21, 2021, indicating strong confidence in its potential growth [1] Group 1: Company Overview - Cytek Biosciences is highlighted for its innovative approach in the equity research space, suggesting it has a competitive edge in the market [1] - The company is part of a broader investment strategy that includes a fundamentals-based portfolio and insights from institutional investors [1] Group 2: Investment Strategy - The investment group Beyond the Wall Investing offers features such as weekly analysis, short-term trade alerts based on technical signals, and community engagement for investors [1] - There is a potential for initiating a long position in CTKB within the next 72 hours, indicating a strategic move based on current market conditions [1]

Core Viewpoint - Cytek Biosciences, Inc. has announced a new stock repurchase program for up to $50 million of its common stock, set to begin on January 1, 2025, following the expiration of the existing program on December 31, 2024 [1]. Summary by Relevant Sections Stock Repurchase Program - The Board of Directors has approved a stock repurchase program for an additional aggregate of $50 million [1]. - The new program will commence on January 1, 2025, and will remain effective until December 31, 2025, unless modified by the Board [1]. - The program does not obligate the company to acquire any specific amount of common stock and may be modified or suspended at the company's discretion [3]. Execution of the Program - Repurchases under the 2025 program will be conducted in the open market and/or through privately negotiated transactions [8]. - The timing and amount of repurchases will depend on various factors, including liquidity, cash flow, and market conditions [8]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes patented Full Spectrum Profiling technology to enhance cell analysis tools [9]. - The company's product offerings include core FSP instruments, reagent preparation systems, and various detection technologies, providing a comprehensive suite of solutions for customers [9]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [9].

Company Participation - Cytek Biosciences, Inc. will participate in the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2024 [1][2] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP™) technology to deliver high-resolution, high-content, and high-sensitivity cell analysis [3] - The FSP platform includes core instruments such as the Cytek Aurora™ and Northern Lights™ systems, as well as other products like the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [3] - Cytek is headquartered in Fremont, California, with global offices and distribution channels [3] Product Usage - Cytek's products are intended for research use only, with exceptions for the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [4] Information Distribution - The company utilizes its website, LinkedIn page, and X (formerly Twitter) account for distributing material information and compliance with disclosure obligations under Regulation FD [5]

Core Insights - Cytek Biosciences, Inc. has been awarded "Overall BioTech Company of the Year" in the fourth annual BioTech Breakthrough Awards program, recognizing its significant contributions to the biotechnology sector [1] - The BioTech Breakthrough Awards program evaluates and acknowledges outstanding life sciences and biotechnology companies globally, with thousands of nominations from 14 countries this year [1] Company Overview - Cytek is recognized as a pioneer in spectral flow cytometry, known for its innovative approach that enhances the understanding of cell biology, immunology, oncology, and targeted therapeutic methodologies [2] - The company offers advanced cell analysis tools through its patented Full Spectrum Profiling™ (FSP™) technology, which includes core instruments like the Cytek Aurora™ and Northern Lights™ systems, as well as a range of other products and services [2][6] Industry Impact - Cytek's deep engagement with the cell analysis community has led to over 2,100 peer-reviewed articles published in prominent academic journals, showcasing the effectiveness of its products in addressing critical challenges [3] - The company aims to make flow cytometry more accessible, thereby facilitating a broader range of discoveries and equipping scientists with essential tools for research and innovation [4][5] Technology and Products - Cytek's FSP platform is designed to deliver high-resolution, high-content, and high-sensitivity cell analysis, utilizing the full spectrum of fluorescent signals for enhanced multiplexing capabilities [6] - The product lineup includes the Cytek Aurora™ CS system for cell sorting, flow cytometers, imaging products under the Amnis® and Guava® brands, and a digital ecosystem known as Cytek Cloud [2][6] Leadership Perspective - The CEO of Cytek, Wenbin Jiang, emphasized the transformative potential of data collection and interpretation in cell analysis, highlighting the company's commitment to making flow cytometry technology more accessible for impactful research outcomes [5]

Core Insights - Cytek Biosciences has launched the Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system, marking a significant advancement in small particle detection for various research fields [1][3] - The ESP Detection Option allows for the study and sorting of particles as small as 70 nm, enhancing the ability to analyze exosomes and extracellular vesicles (EVs), which are crucial for cell communication and therapeutic delivery [2][3] - The Cytek Aurora CS system utilizes Full Spectrum Profiling™ (FSP™) technology, enabling seamless assay transfer and supporting downstream applications like single-cell RNA sequencing and proteomics [3][4] Company Overview - Cytek Biosciences is a leading cell analysis solutions company, known for its high-resolution and high-sensitivity cell analysis tools, including the Cytek Aurora™ and Northern Lights™ systems [5] - The company is headquartered in Fremont, California, and has a global presence with distribution channels [5] - Cytek's innovative approach focuses on multiplexing capabilities and precision in cell analysis, positioning the company at the forefront of exosome and EV research [4][5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Brendan Smith - TD Cowen Mason Carrico - Stephens John Barnidge - Piper Sandler Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I'd like to welcome everyone to the Cytek Biosciences' Thi ...